← Compounds
BPC-157
peptide · headline503A · PCAC-pendingPromotes angiogenesis
Summary
BPC-157 is a synthetic peptide derived from a sequence found in human gastric juice. It has been extensively studied in rodent models for its effects on healing, angiogenesis, and inflammation reduction. Though widely researched, it is not approved for human or veterinary use.
How it works
- Promotes angiogenesis
- Enhances nitric oxide production
- Upregulates VEGF signaling
- Increases GH receptor expression in tendon fibroblasts
- Stabilizes microvascular endothelium
- Accelerates fibroblast migration and F-actin formation
Dosing
- unit: mglow dose: 0.25frequency: 2x dailyhigh dose: 1standard dose: 0.5administration route: Subcutaneous (SQ)
- unit: mglow dose: 0.5frequency: dailyhigh dose: 2standard dose: 1administration route: Oral
Cycling
- Daily injections for 4–6 weeks, then reassess healing response.
Side effects
common: ["Anxiety and panic attacks (frequently user-reported)","Nausea, fatigue, loss of appetite (user-reported)","Insomnia and sleep disturbances (user-reported)","Heart palpitations (user-reported)"]
warnings: ["Depression and anhedonia (user-reported)","Contamination risk: 30% of online peptides contain incorrect sequences; 65% exceed endotoxin thresholds (quality study)"]
Chemistry & PK
sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
half life: Estimated ~4 hours (based on animal data; no human PK studies published).
degradation: Predominantly metabolized in the liver and intestines.
molecular weight: 1419.53552
molecular formula: C62H98N16O22
tissue specificity: Demonstrated efficacy in gastric tissues and musculoskeletal system.
Verified citations
3 · PubMed-checked- The promoting effect of pentadecapeptide BPC 157 on tendon healing.mechanismPMID 21030672 ↗
- BPC 157 and its role in accelerating musculoskeletal soft tissue healing.reviewPMID 30915550 ↗
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide.reviewPMID 40005999 ↗
Used for
!
Warning — BPC-157 crash risk in post-viral/ME-CFS
Post-viral/ME-CFS patients report crashing at standard dose; microdose 10–25%.
Legal / compounding
503A · PCAC-pending
Legal status is a hard gate: non-compoundable or delisted agents cannot be filled and are blocked from protocol export. Keep 503A status current.